

Development of a Candidate Therapeutic Antibody Targeting CTHRC1 for the Treatment of Triple-Negative Breast Cancer

Prestige Biopharma IDC



ONCOLOGY	Candidate
Product Type	Antibody
Indication	TNBC
Target	CTHRC1 (Collagen Triple Helix Repeat Containing 1)
MoA(Mechanism of Action)	1) Directly promoting cancer cell growth and migration 2) Acting as a potent endothelial activator that promotes angiogenesis 3) Remodeling cancer extracellular matrix (ECM) by activating cancer-associated fibroblasts
Competitiveness	First-in-Class antibody drug to target CTHRC1, as a tumor microenvironment modulator with expandable modality ✓ Wide applicability by targeting ECM molecule ✓ Inhibition of tumor growth and metastasis ✓ Enhanced drug permeability to solid tumors
Development Stage	Candidate
Route of Administration	Intravenous (I.V.)

Any unauthorized distribution or reproduction of this material is strictly prohibited.